



Supplemental Figure 4. Baseline concentrations of immune mediators in COVID-19 patients treated with Remdesivir (RDV). Scatter plots of baseline immune mediator levels in plasma samples of COVID-19 patients before RDV treatment. All patients (n=27) were receiving supplemental oxygen and not intubated prior to treatment. Patients were categorized based on their eventual disease progression to requiring intubation (Non-responders, median 7 days post-illness onset (PIO), n=6), or not (Responders, median 9 days PIO, n=21). Immune mediators were grouped based on their association with **(A)** T cells, **(B)** growth and recovery, or **(C)** inflammation. Statistical analyses were performed with Mann Whitney U test (* $P < 0.05$; ** $P < 0.01$). Immune mediator levels for healthy controls (n=23) are indicated by the black dotted line. Patient samples with concentration out of measurement range are presented as the value of Limit of Quantification (LOQ).